Retatrutide is a triple‑agonist peptide that acts on three key hormone receptors: GLP‑1 (glucagon‑like peptide‑1), GIP (glucose‑dependent insulinotropic polypeptide), and Glucagon. By engaging all three pathways, Retatrutide is designed to support significant reductions in body fat, improve insulin sensitivity and glucose control, and increase energy expenditure and metabolic rate.
